Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 101 to 110 of 2432 total matches.
Nalmefene Returns for Reversal of Opioid Overdose
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
Nalmefene Returns for Reversal of Opioid Overdose
Table 1. Pharmacology of Nalmefene
Class Opioid ...
The FDA has approved a generic injectable formulation
of the opioid antagonist nalmefene (Purdue) for the
management of known or suspected opioid overdose.
Revex, the reference product, was withdrawn from the
market in 2008 for commercial reasons.
New Advertisement for An Old Antihistamine
The Medical Letter on Drugs and Therapeutics • Jan 22, 1993 (Issue 888)
FOR
ONLINE USERS
NEW ADVERTISEMENTS FOR AN OLD ANTIHISTAMINE
Advertisements for clemastine (Tavist-1 ...
Advertisements for clemastine (Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24, 1979) that has now become available without a prescription.
Drugs For Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001 (Issue 1095)
of butoconazole nitrate 2% cream (Gynazole 1) is the newest addition. Fluconazole (Diflucan) is approved ...
Many drugs, mostly azole derivatives, are marketed in the USA for topical treatment of vulvovaginal candidiasis. A single-dose, sustained-release formulation of butoconazole nitrate 2% cream (Gynazole 1) is the newest addition. Fluconazole (Diflucan) is approved for single-dose oral treatment.
Continuous Glucose Monitoring
The Medical Letter on Drugs and Therapeutics • May 02, 2011 (Issue 1363)
treatment of diabetes. Since the last Medical
Letter issue reviewing such devices,1 some new devices ...
A variety of continuous glucose monitoring (CGM)
devices have been used in an effort to reduce the hypoglycemia
and wide glucose excursions that complicate
insulin treatment of diabetes. Since the last Medical
Letter issue reviewing such devices, some new devices
and some new data on old devices have become available.
The devices currently marketed in the US for personal
use are listed in Table 1.
An EUA for Sotrovimab for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
of progressing to severe disease, including
hospitalization and death.1
Two other monoclonal
antibody ...
The investigational monoclonal antibody sotrovimab
(VIR-7831; GSK/Vir Biotechnology) has been granted
an FDA Emergency Use Authorization (EUA) for
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death.1 Two other monoclonal
antibody regimens are authorized for the same
indication: casirivimab (REGN10933) and imdevimab
(REGN10987) administered together, and bamlanivimab (LY-CoV555) and etesevimab (LYCoV016)
administered together.
The FDA revoked its EUA...
Naproxen/Esomeprazole (Vimovo)
The Medical Letter on Drugs and Therapeutics • Sep 20, 2010 (Issue 1347)
have a protective effect
on the gastric mucosa. Up to 40% of chronic NSAID
users report having dyspepsia, and 1-2 ...
The FDA has approved the marketing of Vimovo
(AstraZeneca), a fixed-dose combination of the nonsteroidal
anti-inflammatory drug (NSAID) naproxen
and the proton pump inhibitor (PPI) esomeprazole, for
symptomatic relief of osteoarthritis, rheumatoid arthritis
and ankylosing spondylitis and to decrease the risk
of developing gastric ulcers in patients at risk for
NSAID-associated ulcers.
Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
-linked
recessive deficiency of coagulation factor VIII that
occurs in about 1 in 5000 male births ...
The FDA has approved emicizumab-kxwh (Hemlibra –
Genentech), a subcutaneously injected, factor IXa- and
X-directed antibody, for routine prophylaxis to
prevent or reduce bleeding episodes in patients with
hemophilia A. Emicizumab is not recommended for
treatment of bleeding.
Riociguat (Adempas) for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 03, 2014 (Issue 1437)
Table 1. Pharmacology
Drug class Soluble guanylate cyclase (sGC) stimulator
Route Oral
Formulation ...
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension
(CTEPH) following surgery or when surgery is not an
option. It is the first drug to be approved for treatment
of CTEPH.
Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
. Pharmacologic
treatment has included off-label use of timed loop
diuretics and desmopressin.1,2
Table 1 ...
The FDA has approved a sublingual tablet (Nocdurna –
Ferring) and a nasal spray (Noctiva – Avadel) formulation
of desmopressin acetate for treatment of nocturia due to
nocturnal polyuria in adults who wake up ≥2 times per
night to void. Nocdurna and Noctiva are the first two
products to be approved in the US for this indication.
Higher-strength nasal spray and oral tablet formulations
of desmopressin (DDAVP, and others) have been available
for years for treatment of diabetes insipidus and primary
nocturnal enuresis (bedwetting in children). In 2007, the
indication for primary...
Adapalene-Benzoyl Peroxide (Epiduo) for Acne
The Medical Letter on Drugs and Therapeutics • Apr 20, 2009 (Issue 1310)
Epiduo gel (Galderma), a fixed-dose combination of
adapalene 0.1% (Differin), a synthetic retinoid ...
Epiduo gel (Galderma), a fixed-dose combination of adapalene 0.1% (Differin), a synthetic retinoid analog, and benzoyl peroxide (BPO) 2.5%, an oxidizing agent, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old.